Does lymphoma cause hair loss? This is one of the most common concerns raised by patients following a lymphoma diagnosis. In most cases, hair loss is not caused by lymphoma itself but is a well-recognised side effect of treatments such as chemotherapy and radiotherapy. However, certain rare forms of lymphoma — particularly cutaneous T-cell lymphoma — can directly affect the scalp and hair follicles. Understanding the distinction between treatment-related and disease-related hair loss is essential for managing expectations and accessing the right support throughout your care.
Summary: Lymphoma does not typically cause hair loss directly; hair loss is most commonly a side effect of chemotherapy or radiotherapy used to treat the disease, though rare cutaneous lymphomas can directly affect the scalp and hair follicles.
- Chemotherapy regimens such as ABVD and CHOP are the most common cause of hair loss in lymphoma patients, targeting rapidly dividing cells including hair follicles.
- Cutaneous T-cell lymphoma (CTCL) and folliculotropic mycosis fungoides can directly infiltrate the scalp, causing patchy or scarring alopecia.
- Radiotherapy-related hair loss is localised to the treated area and may be permanent at higher doses, unlike the generalised alopecia seen with chemotherapy.
- Scalp cooling (cold cap therapy) is often not recommended for haematological malignancies such as lymphoma due to concerns about creating a sanctuary site for cancer cells.
- Telogen effluvium — diffuse hair shedding triggered by physiological or emotional stress — can occur following a lymphoma diagnosis and is generally self-limiting.
- NHS wigs may be available for eligible patients; availability and charges vary by NHS Trust and across the four UK nations.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
Can Lymphoma Cause Hair Loss?
Lymphoma itself rarely causes hair loss directly; the most common cause is chemotherapy or radiotherapy, though cutaneous lymphomas such as CTCL can damage scalp hair follicles and cause localised alopecia.
Not sure if this is normal? Chat with one of our pharmacists →
Lymphoma itself — the cancer of the lymphatic system — does not typically cause hair loss directly. Hair loss in people with lymphoma is most commonly a side effect of the treatments used to manage the disease, particularly chemotherapy and, in some cases, radiotherapy. It is important to distinguish between hair loss caused by the cancer itself and hair loss caused by its treatment, as the mechanisms and management strategies differ.
That said, there are specific and relatively rare forms of lymphoma that can directly affect the skin and scalp, potentially leading to localised hair loss. Cutaneous T-cell lymphoma (CTCL), for example, is a type of non-Hodgkin lymphoma that originates in the skin and can cause patches, plaques, or tumours on the scalp, which may disrupt hair follicles and result in hair thinning or loss in affected areas. This hair loss may be non-scarring or, in some cases — particularly in folliculotropic mycosis fungoides, where lymphoma cells infiltrate the hair follicle — scarring in nature. This is distinct from the generalised hair loss (alopecia) seen with systemic chemotherapy.
It is also worth noting that some targeted therapies and immunotherapies used in lymphoma treatment — such as brentuximab vedotin or checkpoint inhibitors — can occasionally cause hair changes, although significant alopecia is less common with these agents than with conventional cytotoxic chemotherapy.
The physical and psychological stress of a lymphoma diagnosis can also contribute to a temporary form of hair shedding known as telogen effluvium. This condition occurs when significant physiological or emotional stress causes a large number of hair follicles to enter the resting (telogen) phase simultaneously, leading to diffuse shedding several weeks later. While distressing, telogen effluvium is generally self-limiting and hair typically regrows once the underlying stressor is addressed. If you notice unexpected hair loss following a lymphoma diagnosis, it is always advisable to discuss this with your clinical team to identify the most likely cause.
| Type of Hair Loss | Cause | Pattern | Likely Permanence | Management |
|---|---|---|---|---|
| Chemotherapy-induced alopecia (CIA) | Cytotoxic drugs (e.g. ABVD, CHOP) targeting rapidly dividing cells including hair follicles | Generalised; scalp, brows, lashes, body hair; onset 2–4 weeks post first cycle | Usually temporary; regrowth expected after treatment ends | Scalp cooling (discuss suitability with oncology team); gentle hair care; NHS wig referral |
| Radiotherapy-related hair loss | Radiotherapy directed at head or neck | Localised to treated area only | Dose-dependent; low dose — regrowth likely; high dose — may be permanent | Protective headwear; discuss expected regrowth timeline with clinical team |
| Cutaneous lymphoma-related hair loss | Direct follicular infiltration by lymphoma cells (e.g. CTCL, folliculotropic mycosis fungoides) | Patchy alopecia on scalp; may be non-scarring or scarring | Scarring alopecia may be permanent, especially in folliculotropic mycosis fungoides | Treatment of underlying cutaneous lymphoma; dermatology/oncology review |
| Targeted and immunotherapy-related hair changes | Agents such as brentuximab vedotin or checkpoint inhibitors | Hair thinning or texture changes; generally mild | Usually less severe than CIA; often reversible | Monitor and report changes via MHRA Yellow Card Scheme; discuss with oncology team |
| Telogen effluvium | Physiological or psychological stress of diagnosis or treatment | Diffuse shedding; onset several weeks after stressor | Temporary; self-limiting once underlying stressor resolves | Psychological support; Macmillan Cancer Support or Lymphoma Action resources |
Types of Hair Loss Associated with Lymphoma
Hair loss in lymphoma can result from chemotherapy, radiotherapy, cutaneous lymphoma infiltration, targeted therapies, or stress-related telogen effluvium, each with a different prognosis and management approach.
Understanding the different types of hair loss that may occur in the context of lymphoma can help patients and carers know what to expect and when to seek further advice.
Chemotherapy-induced alopecia (CIA) is the most common form of hair loss experienced by people undergoing lymphoma treatment. Many chemotherapy regimens used for Hodgkin and non-Hodgkin lymphoma — such as ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) or CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) — are associated with significant hair loss. These drugs target rapidly dividing cells, which includes hair follicle cells. Hair loss typically begins two to four weeks after the first cycle of chemotherapy and may affect the scalp, eyebrows, eyelashes, and body hair. In most cases, hair regrows after treatment ends, though texture and colour may temporarily differ.
Radiotherapy-related hair loss is localised to the area being treated. If radiotherapy is directed at the head or neck — for example, in the management of certain lymphomas affecting the brain or cervical lymph nodes — hair loss in that specific region may occur. The extent and permanence of hair loss is dose-dependent: at lower doses, regrowth is usually expected within a few months of completing treatment, whereas at higher doses, hair loss may be permanent. Unlike chemotherapy-induced alopecia, regrowth after radiotherapy is therefore less predictable.
Cutaneous lymphoma-related hair loss occurs when lymphoma directly infiltrates the skin and scalp. In conditions such as CTCL or primary cutaneous follicle centre lymphoma, tumour cells can damage hair follicles, causing patchy alopecia that may be non-scarring or scarring depending on the degree of follicular involvement. Folliculotropic mycosis fungoides in particular is associated with a higher risk of scarring alopecia.
Targeted and immune therapy-related hair changes may occur with some newer agents used in lymphoma, including brentuximab vedotin and checkpoint inhibitors. Hair thinning or texture changes are occasionally reported, though these are generally less severe than CIA.
Telogen effluvium, as mentioned, can also occur as a stress response. Each type of hair loss has a different prognosis and management approach, making accurate identification important.
Managing Hair Loss During Lymphoma Treatment
Scalp cooling is often unsuitable for lymphoma patients due to sanctuary site concerns, but practical measures including gentle hair care, NHS wigs, and psychological support are available.
For many patients, hair loss is one of the most emotionally challenging aspects of lymphoma treatment. While it is often temporary, it can significantly affect self-image, confidence, and psychological wellbeing. A range of practical and clinical strategies are available to help manage this side effect.
Experiencing these side effects? Our pharmacists can help you navigate them →
Scalp cooling (cold cap therapy) is one of the most widely used interventions to reduce chemotherapy-induced hair loss. By cooling the scalp during chemotherapy infusions, blood vessels constrict, reducing the amount of chemotherapy drug reaching hair follicles. NICE has assessed scalp cooling systems (including devices such as those reviewed in NICE Medtech Innovation Briefings) as a supportive measure in oncology. However, it is important to note that scalp cooling is commonly offered for patients receiving chemotherapy for solid tumours, but is often not recommended for people with haematological malignancies such as lymphoma. This is because of a theoretical concern that cooling the scalp could reduce drug delivery to any lymphoma cells present in the scalp or circulating blood, potentially creating a sanctuary site. The decision about whether scalp cooling is appropriate is made on an individual basis by your oncology team. Macmillan Cancer Support provides detailed guidance on scalp cooling suitability for people with blood cancers.
Practical measures that may help include:
-
Using gentle, sulphate-free shampoos and avoiding heat styling tools, hair dye, and chemical treatments during chemotherapy
-
Cutting hair short before treatment begins, which some patients find makes the transition easier
-
Wearing soft headwear such as cotton caps or bamboo scarves to protect a sensitive scalp
-
Exploring wigs and hairpieces — you may be entitled to an NHS wig; however, availability and any associated charges vary by NHS Trust and across the four UK nations. Ask your oncology team or clinical nurse specialist about local provision and referral to a hospital prosthetics or appliances service
-
Cosmetic options for eyebrows and eyelashes, such as brow pencils or false lashes, which some patients find helpful during treatment
Psychological support is equally important. Many cancer centres offer access to specialist oncology nurses, counsellors, and support groups. Organisations such as Lymphoma Action and Macmillan Cancer Support provide dedicated resources for people experiencing treatment-related hair loss. Addressing the emotional impact of alopecia is a recognised part of holistic cancer care and should not be overlooked.
If you experience any unexpected side effects from your treatment — including hair changes — you or your carer can report these to the Medicines and Healthcare products Regulatory Agency (MHRA) via the Yellow Card Scheme at yellowcard.mhra.gov.uk.
When to Speak to Your Clinical Team
Contact your clinical team if hair loss is unexpectedly severe, the scalp shows signs of infection or skin changes, or hair has not regrown within three months of completing chemotherapy.
Hair loss during lymphoma treatment is common and, in most cases, expected. However, there are certain circumstances in which it is important to contact your GP, oncology nurse, or specialist without delay.
Contact your clinical team if you notice:
-
Hair loss that is more severe or rapid than anticipated
-
Scalp pain, redness, blistering, or signs of infection
-
Patchy hair loss with skin changes such as scaling, ulceration, or thickened plaques — which could indicate cutaneous lymphoma involvement
-
Hair that has not begun to regrow within approximately three months of completing chemotherapy; if there is still no visible regrowth by six months, discuss this with your team
-
Significant psychological distress related to hair loss that is affecting your daily life or mental health
If you develop a fever, chills, or any signs of infection whilst receiving chemotherapy or other systemic anti-cancer therapy, do not wait for a routine appointment. Contact your 24-hour acute oncology or chemotherapy helpline immediately — the number should be provided in your treatment information. Infection during chemotherapy can be serious and requires urgent assessment.
If you have not yet started treatment and are experiencing unexplained hair loss alongside other symptoms — such as swollen lymph nodes, night sweats, unexplained weight loss, or persistent fatigue — it is important to seek a medical assessment promptly. These symptoms together may warrant investigation, and your GP can arrange appropriate blood tests and referrals in line with NICE guidance on suspected haematological cancers (NICE NG12: Suspected cancer: recognition and referral).
For those already under the care of an oncology team, your key worker or clinical nurse specialist (CNS) is often the best first point of contact for concerns about treatment side effects, including hair loss. They can provide tailored advice, refer you to supportive care services, and liaise with your wider multidisciplinary team as needed.
Remember that hair loss, whilst distressing, is a recognised and manageable aspect of lymphoma treatment for many patients. Open communication with your clinical team ensures you receive the right support at every stage of your care.
Frequently Asked Questions
Does lymphoma itself cause hair loss, or is it the treatment?
In the vast majority of cases, hair loss in lymphoma patients is caused by chemotherapy or radiotherapy rather than the lymphoma itself. The exception is certain cutaneous lymphomas, such as cutaneous T-cell lymphoma, which can directly infiltrate the scalp and damage hair follicles, leading to localised hair loss.
Will my hair grow back after lymphoma chemotherapy?
For most people, hair begins to regrow within a few weeks to months of completing chemotherapy, though the texture or colour may temporarily differ from before treatment. If there is no visible regrowth within three to six months of finishing treatment, you should discuss this with your oncology team.
Can I use a cold cap to prevent hair loss during lymphoma treatment?
Scalp cooling (cold cap therapy) is frequently not recommended for people with haematological cancers such as lymphoma, due to a theoretical risk of reducing drug delivery to lymphoma cells in the scalp, potentially creating a sanctuary site. Your oncology team will assess whether scalp cooling is appropriate for your individual situation.
Am I entitled to a free NHS wig if I lose my hair during lymphoma treatment?
NHS wigs may be available to eligible patients undergoing cancer treatment, but provision and any associated charges vary between NHS Trusts and across England, Scotland, Wales, and Northern Ireland. Ask your clinical nurse specialist or oncology team about local availability and how to access a referral.
What is the difference between hair loss from chemotherapy and hair loss from radiotherapy?
Chemotherapy-induced hair loss is typically generalised, affecting the whole scalp and often eyebrows, eyelashes, and body hair, and usually reverses after treatment ends. Radiotherapy-related hair loss is localised to the treated area and may be permanent at higher doses, making regrowth less predictable than with chemotherapy.
Can stress from a lymphoma diagnosis cause hair loss on its own?
Yes — significant physical or emotional stress, including that associated with a cancer diagnosis, can trigger telogen effluvium, a condition where large numbers of hair follicles simultaneously enter the resting phase, causing diffuse shedding several weeks later. This type of hair loss is generally temporary and resolves once the underlying stressor is managed.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
